Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 139 entries
Sorted by: Best Match Show Resources per page
Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data.

Biopharmaceutics & drug disposition

Stockmann C, Spigarelli MG, Healy DP, Gottschlich MM, Kagan R, Balch AH, Sherwin C.
PMID: 25766031
Biopharm Drug Dispos. 2015 Sep;36(6):405-409. doi: 10.1002/bdd.1949. Epub 2015 Apr 21.

With traditional non-compartmental methods, it is challenging to deconstruct plasma concentration versus time curves to assess the influence of individual doses. This study describes the application of a mathematical approach used to deconstruct a single dose curve using data...

Cite
Stockmann C, Spigarelli MG, Healy DP, et al. Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. Biopharm Drug Dispos. 2015;36(6):405-409doi: 10.1002/bdd.1949.
Stockmann, C., Spigarelli, M. G., Healy, D. P., Gottschlich, M. M., Kagan, R., Balch, A. H., & Sherwin, C. (2015). Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. Biopharmaceutics & drug disposition, 36(6), 405-409. https://doi.org/10.1002/bdd.1949
Stockmann, Chris, et al. "Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data." Biopharmaceutics & drug disposition vol. 36,6 (2015): 405-409. doi: https://doi.org/10.1002/bdd.1949
Stockmann C, Spigarelli MG, Healy DP, Gottschlich MM, Kagan R, Balch AH, Sherwin C. Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. Biopharm Drug Dispos. 2015 Sep;36(6):405-409. doi: 10.1002/bdd.1949. Epub 2015 Apr 21. PMID: 25766031.
Copy Download .nbib Format: NLM
Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis.

Emerging microbes & infections

Li J, Gao X, Luo T, Wu J, Sun G, Liu Q, Jiang Y, Zhang Y, Mei J, Gao Q.
PMID: 26038513
Emerg Microbes Infect. 2014 Mar;3(3):e19. doi: 10.1038/emi.2014.21. Epub 2014 Mar 12.

To evaluate the association between mutations in the genes gyrA/B and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis, a total of 80 ofloxacin-resistant isolates collected in 2009 by the Shanghai Municipal Centers for Disease Control and...

Cite
Li J, Gao X, Luo T, et al. Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis. Emerg Microbes Infect. 2014;3(3):e19doi: 10.1038/emi.2014.21.
Li, J., Gao, X., Luo, T., Wu, J., Sun, G., Liu, Q., Jiang, Y., Zhang, Y., Mei, J., & Gao, Q. (2014). Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis. Emerging microbes & infections, 3(3), e19. https://doi.org/10.1038/emi.2014.21
Li, Jing, et al. "Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis." Emerging microbes & infections vol. 3,3 (2014): e19. doi: https://doi.org/10.1038/emi.2014.21
Li J, Gao X, Luo T, Wu J, Sun G, Liu Q, Jiang Y, Zhang Y, Mei J, Gao Q. Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis. Emerg Microbes Infect. 2014 Mar;3(3):e19. doi: 10.1038/emi.2014.21. Epub 2014 Mar 12. PMID: 26038513; PMCID: PMC3974338.
Copy Download .nbib Format: NLM
Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains.

International journal of microbiology

Park M, Rafii F.
PMID: 25587280
Int J Microbiol. 2014;2014:456979. doi: 10.1155/2014/456979. Epub 2014 Dec 21.

Fluoroquinolone resistance affects toxin production of Clostridium perfringens strains differently. To investigate the effect of fluoroquinolone resistance selection on global changes in metabolic activities and drug susceptibilities, four C. perfringens strains and their norfloxacin-, ciprofloxacin-, and gatifloxacin-resistant mutants were...

Cite
Park M, Rafii F. Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains. Int J Microbiol. 2014;2014:456979doi: 10.1155/2014/456979.
Park, M., & Rafii, F. (2014). Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains. International journal of microbiology, 2014456979. https://doi.org/10.1155/2014/456979
Park, Miseon, and Rafii, Fatemeh. "Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains." International journal of microbiology vol. 2014 (2014): 456979. doi: https://doi.org/10.1155/2014/456979
Park M, Rafii F. Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains. Int J Microbiol. 2014;2014:456979. doi: 10.1155/2014/456979. Epub 2014 Dec 21. PMID: 25587280; PMCID: PMC4283427.
Copy Download .nbib Format: NLM
Gyrase A Mutations in Campylobacter Associated with Decreased Susceptibility to Different Fluoroquinolones.

Journal of food protection

Whitehouse CA, Zhao S, Mukherjee S, Tate H, Bodeis-Jones S, Young S, Gaines S, McDermott P.
PMID: 28994613
J Food Prot. 2017 Oct 10;1863-1866. doi: 10.4315/0362-028X.JFP-17-129. Epub 2017 Oct 10.

Campylobacter is a leading cause of foodborne diarrheal illness worldwide, and the emergence of antimicrobial-resistant strains is a major global public health concern. The goal of this study was to compare the activity of different fluoroquinolone antibiotics against ciprofloxacin-resistant...

Cite
Whitehouse CA, Zhao S, Mukherjee S, et al. Gyrase A Mutations in Campylobacter Associated with Decreased Susceptibility to Different Fluoroquinolones. J Food Prot. 2017;1863-1866doi: 10.4315/0362-028X.JFP-17-129.
Whitehouse, C. A., Zhao, S., Mukherjee, S., Tate, H., Bodeis-Jones, S., Young, S., Gaines, S., & McDermott, P. (2017). Gyrase A Mutations in Campylobacter Associated with Decreased Susceptibility to Different Fluoroquinolones. Journal of food protection, 1863-1866. https://doi.org/10.4315/0362-028X.JFP-17-129
Whitehouse, Chris A, et al. "Gyrase A Mutations in Campylobacter Associated with Decreased Susceptibility to Different Fluoroquinolones." Journal of food protection vol. (2017): 1863-1866. doi: https://doi.org/10.4315/0362-028X.JFP-17-129
Whitehouse CA, Zhao S, Mukherjee S, Tate H, Bodeis-Jones S, Young S, Gaines S, McDermott P. Gyrase A Mutations in Campylobacter Associated with Decreased Susceptibility to Different Fluoroquinolones. J Food Prot. 2017 Oct 10;1863-1866. doi: 10.4315/0362-028X.JFP-17-129. Epub 2017 Oct 10. PMID: 28994613.
Copy Download .nbib Format: NLM
Gatifloxacin Therapy in Otitis Media in Children.

Current infectious disease reports

Brook I.
PMID: 15847716
Curr Infect Dis Rep. 2005 May;7(3):163-164. doi: 10.1007/s11908-005-0028-7.

No abstract available.

Cite
Brook I. Gatifloxacin Therapy in Otitis Media in Children. Curr Infect Dis Rep. 2005;7(3):163-164doi: 10.1007/s11908-005-0028-7.
Brook, I. (2005). Gatifloxacin Therapy in Otitis Media in Children. Current infectious disease reports, 7(3), 163-164. https://doi.org/10.1007/s11908-005-0028-7
Brook, Itzhak. "Gatifloxacin Therapy in Otitis Media in Children." Current infectious disease reports vol. 7,3 (2005): 163-164. doi: https://doi.org/10.1007/s11908-005-0028-7
Brook I. Gatifloxacin Therapy in Otitis Media in Children. Curr Infect Dis Rep. 2005 May;7(3):163-164. doi: 10.1007/s11908-005-0028-7. PMID: 15847716.
Copy Download .nbib Format: NLM
Skin and skin structure infections: treatment with newer generation fluoroquinolones.

Therapeutics and clinical risk management

Giordano P, Weber K, Gesin G, Kubert J.
PMID: 18360639
Ther Clin Risk Manag. 2007 Jun;3(2):309-17. doi: 10.2147/tcrm.2007.3.2.309.

Skin and skin structure infections (SSSI) are an emerging issue in healthcare. They are responsible for increasing heathcare utilization, both in hospitalizations and intravenous antibiotic use. SSSI are caused by an evolving variety of pathogens, including Gram-positive, Gram-negative, and...

Cite
Giordano P, Weber K, Gesin G, et al. Skin and skin structure infections: treatment with newer generation fluoroquinolones. Ther Clin Risk Manag. 2007;3(2):309-17doi: 10.2147/tcrm.2007.3.2.309.
Giordano, P., Weber, K., Gesin, G., & Kubert, J. (2007). Skin and skin structure infections: treatment with newer generation fluoroquinolones. Therapeutics and clinical risk management, 3(2), 309-17. https://doi.org/10.2147/tcrm.2007.3.2.309
Giordano, Philip, et al. "Skin and skin structure infections: treatment with newer generation fluoroquinolones." Therapeutics and clinical risk management vol. 3,2 (2007): 309-17. doi: https://doi.org/10.2147/tcrm.2007.3.2.309
Giordano P, Weber K, Gesin G, Kubert J. Skin and skin structure infections: treatment with newer generation fluoroquinolones. Ther Clin Risk Manag. 2007 Jun;3(2):309-17. doi: 10.2147/tcrm.2007.3.2.309. PMID: 18360639; PMCID: PMC1936312.
Copy Download .nbib Format: NLM
Investigation on sensitized chemiluminescence systems and their mechanism for five fluoroquinolones.

Analytica chimica acta

Sun H, Li L, Chen X.
PMID: 17723632
Anal Chim Acta. 2006 Aug 25;576(2):192-9. doi: 10.1016/j.aca.2006.06.013. Epub 2006 Jun 16.

The novel chemiluminescence (CL) reaction systems were established for lomefloxacin (LMFX), ofloxacin(OFLX), norfloxacin (NFLX), gatifloxacin (GAFX) and enoxacin (ENX). The sensitized CL emission mechanism was investigated for the five systems by comparing the fluorescence emission with CL spectra. For...

Cite
Sun H, Li L, Chen X. Investigation on sensitized chemiluminescence systems and their mechanism for five fluoroquinolones. Anal Chim Acta. 2006;576(2):192-9doi: 10.1016/j.aca.2006.06.013.
Sun, H., Li, L., & Chen, X. (2006). Investigation on sensitized chemiluminescence systems and their mechanism for five fluoroquinolones. Analytica chimica acta, 576(2), 192-9. https://doi.org/10.1016/j.aca.2006.06.013
Sun, Hanwen, et al. "Investigation on sensitized chemiluminescence systems and their mechanism for five fluoroquinolones." Analytica chimica acta vol. 576,2 (2006): 192-9. doi: https://doi.org/10.1016/j.aca.2006.06.013
Sun H, Li L, Chen X. Investigation on sensitized chemiluminescence systems and their mechanism for five fluoroquinolones. Anal Chim Acta. 2006 Aug 25;576(2):192-9. doi: 10.1016/j.aca.2006.06.013. Epub 2006 Jun 16. PMID: 17723632.
Copy Download .nbib Format: NLM
Oral fluoroquinolones in the treatment of pneumonia, bronchitis and sinusitis.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses

Mittmann N, Jivarj F, Wong A, Yoon A.
PMID: 18159405
Can J Infect Dis. 2002 Sep;13(5):293-300. doi: 10.1155/2002/698146.

BACKGROUND: Despite a relatively large number of clinical studies comparing oral fluoroquinolones to one antibiotic class comparator, there is limited information on the relative efficacy of different fluoroquinolones.OBJECTIVE: To examine the efficacy and tolerability of oral fluoroquinolones in the...

Cite
Mittmann N, Jivarj F, Wong A, et al. Oral fluoroquinolones in the treatment of pneumonia, bronchitis and sinusitis. Can J Infect Dis. 2002;13(5):293-300doi: 10.1155/2002/698146.
Mittmann, N., Jivarj, F., Wong, A., & Yoon, A. (2002). Oral fluoroquinolones in the treatment of pneumonia, bronchitis and sinusitis. The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses, 13(5), 293-300. https://doi.org/10.1155/2002/698146
Mittmann, Nicole, et al. "Oral fluoroquinolones in the treatment of pneumonia, bronchitis and sinusitis." The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses vol. 13,5 (2002): 293-300. doi: https://doi.org/10.1155/2002/698146
Mittmann N, Jivarj F, Wong A, Yoon A. Oral fluoroquinolones in the treatment of pneumonia, bronchitis and sinusitis. Can J Infect Dis. 2002 Sep;13(5):293-300. doi: 10.1155/2002/698146. PMID: 18159405; PMCID: PMC2094884.
Copy Download .nbib Format: NLM
Retractions. Re: "Ethics of administering gatifloxacin for H. pylori infection in asymptomatic veterans" by D. Vaira, A. Zullo, V. de Francesco, G. Scaccianoce and "Ethical issues regarding recent anti-H. pylori clinical studies" by D. Y. Graham .

Alimentary pharmacology & therapeutics

[No authors listed]
PMID: 18194502
Aliment Pharmacol Ther. 2008 Mar 15;27(6):530. doi: 10.1111/j.1365-2036.2008.03602.x.

No abstract available.

Cite
Retractions. Re: "Ethics of administering gatifloxacin for H. pylori infection in asymptomatic veterans" by D. Vaira, A. Zullo, V. de Francesco, G. Scaccianoce and "Ethical issues regarding recent anti-H. pylori clinical studies" by D. Y. Graham . Aliment Pharmacol Ther. 2008;27(6):530doi: 10.1111/j.1365-2036.2008.03602.x.
(2008). Retractions. Re: "Ethics of administering gatifloxacin for H. pylori infection in asymptomatic veterans" by D. Vaira, A. Zullo, V. de Francesco, G. Scaccianoce and "Ethical issues regarding recent anti-H. pylori clinical studies" by D. Y. Graham . Alimentary pharmacology & therapeutics, 27(6), 530. https://doi.org/10.1111/j.1365-2036.2008.03602.x
"Retractions. Re: "Ethics of administering gatifloxacin for H. pylori infection in asymptomatic veterans" by D. Vaira, A. Zullo, V. de Francesco, G. Scaccianoce and "Ethical issues regarding recent anti-H. pylori clinical studies" by D. Y. Graham ." Alimentary pharmacology & therapeutics vol. 27,6 (2008): 530. doi: https://doi.org/10.1111/j.1365-2036.2008.03602.x
Retractions. Re: "Ethics of administering gatifloxacin for H. pylori infection in asymptomatic veterans" by D. Vaira, A. Zullo, V. de Francesco, G. Scaccianoce and "Ethical issues regarding recent anti-H. pylori clinical studies" by D. Y. Graham . Aliment Pharmacol Ther. 2008 Mar 15;27(6):530. doi: 10.1111/j.1365-2036.2008.03602.x. PMID: 18194502.
Copy Download .nbib Format: NLM
Sodium alginate based mucoadhesive system for gatifloxacin and its in vitro antibacterial activity.

Scientia pharmaceutica

Kesavan K, Nath G, Pandit JK.
PMID: 21179327
Sci Pharm. 2010 Oct-Dec;78(4):941-57. doi: 10.3797/scipharm.1004-24. Epub 2010 Sep 26.

The objective of this study was to formulate sodium alginate based ophthalmic mucoadhesive system of gatifloxacin and its in vitro antibacterial potential on pathogenic microorganisms, Staphylococcus aureus and Escherichia coli. Sodium carboxymethylcellulose (NaCMC) was added to the formulations to...

Cite
Kesavan K, Nath G, Pandit JK. Sodium alginate based mucoadhesive system for gatifloxacin and its in vitro antibacterial activity. Sci Pharm. 2010;78(4):941-57doi: 10.3797/scipharm.1004-24.
Kesavan, K., Nath, G., & Pandit, J. K. (2010). Sodium alginate based mucoadhesive system for gatifloxacin and its in vitro antibacterial activity. Scientia pharmaceutica, 78(4), 941-57. https://doi.org/10.3797/scipharm.1004-24
Kesavan, Karthikeyan, et al. "Sodium alginate based mucoadhesive system for gatifloxacin and its in vitro antibacterial activity." Scientia pharmaceutica vol. 78,4 (2010): 941-57. doi: https://doi.org/10.3797/scipharm.1004-24
Kesavan K, Nath G, Pandit JK. Sodium alginate based mucoadhesive system for gatifloxacin and its in vitro antibacterial activity. Sci Pharm. 2010 Oct-Dec;78(4):941-57. doi: 10.3797/scipharm.1004-24. Epub 2010 Sep 26. PMID: 21179327; PMCID: PMC3007603.
Copy Download .nbib Format: NLM
In-vitro Antimycoplasmal Activity of Triclosan in Combination with Fluoroquinolones against Five mycoplasma Species.

Iranian journal of pharmaceutical research : IJPR

Li L, Shen W, Zhang K, Tang X, Guo N, Shen F, Xing M, Liua L, Yuan P, Shi Q, Liang J, Yu L.
PMID: 24250544
Iran J Pharm Res. 2012;11(4):1111-9.

Mycoplasmosis caused by mycoplasma has immensely reduced the performance of commercial animal husbandry, along with prevalence and increase of drug resistance in mycoplasma, thus new agents and therapies are urgently needed. Triclosan is a broad spectrum antimicrobial agent with...

Cite
Li L, Shen W, Zhang K, et al. In-vitro Antimycoplasmal Activity of Triclosan in Combination with Fluoroquinolones against Five mycoplasma Species. Iran J Pharm Res. 2012;11(4):1111-9
Li, L., Shen, W., Zhang, K., Tang, X., Guo, N., Shen, F., Xing, M., Liua, L., Yuan, P., Shi, Q., Liang, J., & Yu, L. (2012). In-vitro Antimycoplasmal Activity of Triclosan in Combination with Fluoroquinolones against Five mycoplasma Species. Iranian journal of pharmaceutical research : IJPR, 11(4), 1111-9.
Li, Lei, et al. "In-vitro Antimycoplasmal Activity of Triclosan in Combination with Fluoroquinolones against Five mycoplasma Species." Iranian journal of pharmaceutical research : IJPR vol. 11,4 (2012): 1111-9.
Li L, Shen W, Zhang K, Tang X, Guo N, Shen F, Xing M, Liua L, Yuan P, Shi Q, Liang J, Yu L. In-vitro Antimycoplasmal Activity of Triclosan in Combination with Fluoroquinolones against Five mycoplasma Species. Iran J Pharm Res. 2012;11(4):1111-9. PMID: 24250544; PMCID: PMC3813145.
Copy Download .nbib Format: NLM
Oxidative stress induced by fluoroquinolones on treatment for complicated urinary tract infections in Indian patients.

Journal of young pharmacists : JYP

Talla V, Veerareddy P.
PMID: 22224037
J Young Pharm. 2011 Oct;3(4):304-9. doi: 10.4103/0975-1483.90242.

The aim of the study is to examine the oxidative stress in patients on fluoroquinolones (ciprofloxacin, levofloxacin, gatifloxacin) therapy for complicated urinary tract infections and to correlate with plasma concentrations at different time intervals. Superoxide dismutase (SOD), glutathione, plasma...

Cite
Talla V, Veerareddy P. Oxidative stress induced by fluoroquinolones on treatment for complicated urinary tract infections in Indian patients. J Young Pharm. 2011;3(4):304-9doi: 10.4103/0975-1483.90242.
Talla, V., & Veerareddy, P. (2011). Oxidative stress induced by fluoroquinolones on treatment for complicated urinary tract infections in Indian patients. Journal of young pharmacists : JYP, 3(4), 304-9. https://doi.org/10.4103/0975-1483.90242
Talla, V, and Veerareddy, Pr. "Oxidative stress induced by fluoroquinolones on treatment for complicated urinary tract infections in Indian patients." Journal of young pharmacists : JYP vol. 3,4 (2011): 304-9. doi: https://doi.org/10.4103/0975-1483.90242
Talla V, Veerareddy P. Oxidative stress induced by fluoroquinolones on treatment for complicated urinary tract infections in Indian patients. J Young Pharm. 2011 Oct;3(4):304-9. doi: 10.4103/0975-1483.90242. PMID: 22224037; PMCID: PMC3249743.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 139 entries